Get the Stockscreener App
5.70
0.70%
-0.04
After Hours:
5.74
0.04
+0.70%
Co Diagnostics Inc stock is traded at $5.70, with a volume of 78,710.
It is down -0.70% in the last 24 hours and down -49.27% over the past month.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
See More
Previous Close:
$5.74
Open:
$5.67
24h Volume:
78,710
Relative Volume:
0.12
Market Cap:
$11.94M
Revenue:
$7.11M
Net Income/Loss:
$-41.28M
P/E Ratio:
-4.1304
EPS:
-1.38
Net Cash Flow:
$-26.84M
1W Performance:
+5.15%
1M Performance:
-49.27%
6M Performance:
-31.41%
1Y Performance:
-81.00%
1-Day Range:
$5.50
$6.17
1-Week Range:
$4.84
$6.17
52-Week Range:
$4.84
$46.50
Co Diagnostics Inc Stock (CODX) Company Profile
Name
Co Diagnostics Inc
Sector
Industry
Phone
(801) 278-9769
Address
4049 SOUTH HIGHLAND DRIVE, SALT LAKE CITY
Compare CODX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CODX
Co Diagnostics Inc
|
5.70 | 12.03M | 7.11M | -41.28M | -26.84M | -1.38 |
|
ABT
Abbott Laboratories
|
127.78 | 219.88B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
97.79 | 141.54B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
366.39 | 133.39B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.31 | 124.82B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
85.85 | 48.84B | 5.88B | 1.34B | 799.60M | 2.3489 |
Co Diagnostics Inc Stock (CODX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-22 | Downgrade | Sidoti | Buy → Neutral |
| Dec-29-21 | Initiated | Sidoti | Buy |
| Mar-29-21 | Downgrade | Maxim Group | Buy → Hold |
| May-20-20 | Upgrade | Maxim Group | Hold → Buy |
| May-18-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-03-20 | Downgrade | Maxim Group | Buy → Hold |
View All
Co Diagnostics Inc Stock (CODX) Latest News
CODX stock plunges to all-time lows on 1-for-30 reverse stock split approval - MSN
Co-Diagnostics, Inc. to Host Booth at the 2024 UHCA/UCAL Fall Convention and Expo on Oct 2-3 - marketscreener.com
CODX Shares Dip Despite Australian Patent Grant for Co-Dx PCR Platform - Finviz
Co-Diagnostics Approves Reverse Stock Split to Maintain Listing - The Globe and Mail
Co-Diagnostics announces 1-for-30 reverse stock split - Yahoo Finance
Institution Moves: Is Co Diagnostics Inc stock a buy in volatile marketsDip Buying & Daily Volume Surge Trade Alerts - moha.gov.vn
Co-Diagnostics (CODX) Announces 1-for-30 Reverse Stock Split - GuruFocus
Co-Diagnostics to Effect a 1-for-30 Reverse Stock Split - marketscreener.com
CODX Stock Plunges To All-Time Lows On 1-for-30 Reverse Stock Split Approval - Stocktwits
Co-Diagnostics stock plunges after announcing 1-for-30 reverse split By Investing.com - Investing.com South Africa
Co-Diagnostics announces 1-for-30 reverse stock split By Investing.com - Investing.com Nigeria
Co-Diagnostics stock plunges after announcing 1-for-30 reverse split - Investing.com India
Biotech Co-Diagnostics shrinks share count 30-to-1 to stay on Nasdaq - Stock Titan
Co-Diagnostics Receives Grant of Australian Patent Covering Co-Dx PCR Platform Technologies - The Malaysian Reserve
Co-Diagnostics Receives Grant of Australian Patent Covering Co-D - GuruFocus
Co-Diagnostics (CODX) Secures Australian Patent for PCR Platform - GuruFocus
Co-diagnostics receives Australian patent for PCR testing platform - Investing.com India
Co-diagnostics receives Australian patent for PCR testing platform By Investing.com - Investing.com Nigeria
New point-of-care PCR tech for flu and COVID secures patent in Australia - Stock Titan
Co-Diagnostics Q3 2025 Earnings Preview - MSN
Aug Breakouts: How resilient is Co Diagnostics Inc. stock in market downturns - Улправда
Can Co Diagnostics Inc. stock sustain market leadershipWeekly Trade Report & Low Drawdown Momentum Trade Ideas - Улправда
Why Co Diagnostics Inc. stock is seen as undervaluedJuly 2025 Update & Stepwise Trade Signal Guides - Улправда
Will Co Diagnostics Inc. stock deliver consistent dividends2025 Support & Resistance & Free High Accuracy Swing Entry Alerts - DonanımHaber
Can Co Diagnostics Inc. stock weather global recession2025 Trading Volume Trends & Reliable Price Breakout Signals - ulpravda.ru
Bond Watch: Is Co Diagnostics Inc. stock a buy in volatile markets2025 Investor Takeaways & Weekly Watchlist for Consistent Profits - DonanımHaber
How resilient is Co Diagnostics Inc. stock in market downturnsPortfolio Risk Summary & AI Forecast Swing Trade Picks - Улправда
Co-Diagnostics Joint Venture, CoSara, Invited to Participate in - GuruFocus
Co-Diagnostics Joint Venture, CoSara, Invited to Participate in 2nd Advanced TB Diagnostics Course in Chennai, India - Barchart.com
Co-Diagnostics Performs Analysis of Influenza Co-Primers® to Con - GuruFocus
Co-Diagnostics (CODX) Validates Efficacy of Influenza and COVID-19 Detection Test - GuruFocus
Co-Diagnostics Performs Analysis of Influenza Co-Primers® to Confirm Reactivity Against Flu A H3N2 Mutation - Nasdaq
Co Diagnostics Inc Stock Analysis and ForecastRisk Mitigation Techniques & Affordable Trading Techniques - earlytimes.in
Certain Warrants of Co-Diagnostics, Inc. are subject to a Lock-Up Agreement Ending on 14-DEC-2025. - marketscreener.com
Certain Restricted Stock Units of Co-Diagnostics, Inc. are subject to a Lock-Up Agreement Ending on 14-DEC-2025. - marketscreener.com
Certain Stock Options of Co-Diagnostics, Inc. are subject to a Lock-Up Agreement Ending on 14-DEC-2025. - marketscreener.com
48,142,582 Common Stock of Co-Diagnostics, Inc. are subject to a Lock-Up Agreement Ending on 14-DEC-2025. - marketscreener.com
Value Recap: Will Co Diagnostics Inc stock deliver consistent dividendsMarket Growth Summary & High Accuracy Swing Entry Alerts - moha.gov.vn
Co-Diagnostics, Arabian Eagle to Develop and Commercialize Co-Dx Tech - Medical Product Outsourcing
Co-Diagnostics Earnings Call: Strategic Moves Amid Financial Struggles - MSN
CapEx per share of Co-Diagnostics, Inc. – MUN:C97 - TradingView — Track All Markets
Co-Diagnostics to Present on Co-Dx™ PCR Platform and AI Integration at Point-of-Care Testing 2025 - Barchart.com
Co-Diagnostics JV, CoSara, to Participate at VIROCON 2025 in Pun - GuruFocus
Co-Diagnostics JV, CoSara, to Participate at VIROCON 2025 in Pune, India - Sahm
Co-Diagnostics (Nasdaq: CODX) JV highlights TB, HPV PoC tests at VIROCON 2025 - Stock Titan
Co Diagnostics Inc Stock (CODX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):